Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Key Highlights
- ➤TSHA-102 encore presentations scheduled October 15–16, 2026, at Child Neurology Society meeting
- ➤TSHA-102 Phase 1/2 REVEAL Part A data highlight multi-domain functional gains
- ➤TSHA-102 targets Rett syndrome’s genetic root cause with one-time intrathecal gene therapy
- ➤TSHA-102 holds FDA Breakthrough Therapy, RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55(th) Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026.
The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting. IRSF poster presentations are available on Taysha’s website.
Get started
Create a free account to read the full story.